Foamix
Rehovot
About Foamix
Foamix has a strong in-house pipeline of drugs for dermatologic, ophthalmologic and gynecologic indications. The Company’s lead product under development is the first-in-class Topical Minocycline Foam addressing large markets in dermatology and ophthalmology. Minocycline foam demonstrated high efficacy and favorable safety in two phase II clinical studies in Acne and Impetigo patients. Foamix Ltd. is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burns as well as ophthalmic disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $197.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jul 2019)
- Ticker: nasdaq:FOMX
- Website: foamix.com
- Phone: (972) 893-1623
Industries & Categories
Clinical Trials, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/foamix-161108 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.